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BACKGROUND: The study was carried out to evaluate the effects of short-term transdermal hormone replacement
therapy (HRT) on glycaemic control, lipid metabolism, C-reactive protein (CRP) and proteinuria in high-risk post-
menopausal women. METHODS: A total of 20 well-controlled type 2 diabetic, hypertensive and 21 well-controlled
glucose-tolerant, hypertensive postmenopausal women were prospectively enrolled. After 12 weeks of transdermal
HRT, the changes in serum lipid sub-fractions, fasting glucose, fructosamine, glycated haemoglobin (HbA1c), CRP,
creatinine, 24 h urine protein levels, creatinine clearance and blood pressure were evaluated. RESULTS: After 12
weeks of treatment, serum total-cholesterol and low-density cholesterols (LDL-cholesterol) appeared slightly
reduced and serum triglyceride slightly elevated, although non-signi®cantly so in both groups. The increase in HDL-
cholesterol (P < 0.05) and reduction in very low density (VLDL)-cholesterol (P < 0.05) levels were signi®cant in
hypertensive patients. Elevation in the Apolipoprotein A1 (P < 0.05) and reduction in the Apolipoprotein B
(P < 0.05) levels were statistically signi®cant in all patients. HRT was associated with signi®cant decreases in serum
fasting glucose (P < 0.05) and fructosamine (P < 0.05) levels in diabetic patients. Serum HbA1c, CRP, creatinine, 24 h
urine protein levels, creatinine clearance and systolic and diastolic blood pressure did not change signi®cantly in
either group. CONCLUSIONS: There were no detrimental effects of transdermal HRT on lipid pro®le, glucose
metabolism, CRP and urine protein levels in our well-controlled diabetic or hypertensive patients. A decision
regarding HRT use should be taken on a case-by-case basis.
Key words: CRP/diabetes/HRT/lipid-glucose metabolism/proteinuria
Introduction
Type 2 diabetes and hypertension are major risk factors for
cardiovascular diseases (CVD), which are associated with
dyslipidaemia (Niskanen et al., 1998; Kaukua et al., 2001;
Camisasca et al., 2002; Jacobsen et al., 2002). Diabetic women
have a 2±5-fold higher risk for cardiovascular disease than age-
matched non-diabetic women (de Stefano et al., 1993; Wilson,
1998). A recent study reported that 17% of postmenopausal
diabetic women used HRT, compared with 39% of non-
diabetics (Keating et al., 1999).
There is a lack of overall agreement about whether
postmenopausal women can use HRT for the purpose of
cardiovascular protection. Although study subjects were rela-
tively old, the results of the Heart and Estrogen/progestin
Replacement Study (HERS) (Hulley et al., 1998) and the
Womens Health Initiative (WHI) Writing Group, (2002)
studies suggested that HRT had no advantages for prevention
of coronary heart disease (CHD). There was an increase in
cardiovascular events in the ®rst year, but, interestingly, fewer
events were seen after 2 years of treatment in the hormone
group in the HERS. On the other hand, it has been reported that
HRT improves lipid±lipoprotein pro®les (Hulley et al., 1998;
Herrington et al., 2000; Shlipak et al., 2000; Erenus et al.,
2001; Sendag et al., 2002; Ranta et al., 2002) and endothelial
and vascular smooth muscle function, and has potentially
bene®cial effects on vascular relaxation in peripheral and
coronary vasculatures (Lieberman et al., 1994; Reis et al.,
1994; Perera et al., 2002). Noticeably, concerns remain about
the use of HRT for cardiovascular protection, which is more
intricate than was initially believed. Although there were some
recent reports on the use of HRT in diabetic or hypertensive
postmenopausal women (Cornu et al., 2000; Cacciatore et al.,
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2001; Darko et al., 2001; Perera et al., 2001, 2002), the effects
of short-term transdermal HRT on glycaemic control, lipid
metabolism, C-reactive protein and urine protein in these high-
risk groups have not been studied adequately.
This study was planned to evaluate the effects of 12 weeks of
transdermal HRT on mean serum lipid sub-fractions, fasting
glucose, fructosamine, glycated haemoglobin (HbA1c),
C-reactive protein (CRP), creatinine, 24 h urine protein levels,
creatinine clearance and blood pressure.
Materials and methods
We prospectively studied 41 subjects, 20 postmenopausal women with
type 2 diabetes and hypertension (DM-HRT group) and 21
postmenopausal women who were glucose-tolerant but hypertensive
(HT-HRT group). Diabetes was diagnosed using the criteria of the
World Health Organization (World Health Organization, 1980) at
least 2 years before entering the study. In order to maintain their
glucose levels in an acceptable range, women with type 2 diabetes
were on dietary management alone (two patients) or taking oral anti-
diabetic drugs that consisted of metformin and sulfonylureas
(18 patients). Each diabetic patient received a diabetic diet with
<30% of total calories as fat, <10% saturated fat, <10% mono-
unsaturated fat and <10% polyunsaturated fat. The women were
instructed not to change their diet. None of them were taking insulin.
All women took a calcium channel blocker (amlodipine 5±10 mg/day)
as an anti-hypertensive drug. Amlodipine, which has no signi®cant
effect on lipid metabolism, was prescribed at least 3 months before the
study. None of the women were taking anti-lipidaemic, corticosteroid
or anti-convulsant therapy. The anti-diabetic and anti-hypertensive
medications were left unchanged during the study.
Menopause was con®rmed by the absence of menstruation for at
least 12 months and by high serum levels of FSH (>30 mIU/ml) and
low serum levels of estradiol (E2) (<20pg/ml). The subjects had not
received HRT previously. Gynaecological examination, comprising
endometrial biopsy and mammogram, were normal in all subjects.
All study subjects received 12 weeks of transdermal continuous
17b-estradiol (0.05 mg/day) with transdermal sequential norethister-
one acetate (NETA) 0.25 mg/day (Estracombi TTS, Novartis,
Switzerland). This work was approved by the local medical ethics
committee and all participants gave informed consent before the onset
of study.
All metabolic and physical examinations were performed at the
onset of the study and then again after 12 weeks of receiving HRT.
Blood pressure was measured with a mercury sphygmomanometer
during two clinical evaluations by an average of three measurements
taken in the sitting position before the morning dose of the anti-
hypertensive therapy. On the fourth day of the third hormonal cycle (in
the estrogen only phase) blood samples were taken after a 10 h fast and
serum total cholesterol (total cholesterol), triglyceride (TG), high
density cholesterol (HDL-cholesterol), VLDL-cholesterol, apolipo-
protein A1 (Apo-A1), apolipoprotein B (Apo-B), serum creatinine
(sCr), urine creatinine (uCr), 24 h urine protein, fructosamine, HbA1c
and glucose levels were determined in an Hitachi 911 automated
analyser by using commercial kits supplied from Roche Diagnostics.
Low-density cholesterol (LDL cholesterol) levels were calculated by
using Friedewald's formula. Serum CRP was turbidimetrically
determined by clinical chemistry system (SPACE, Schiapparelli
Biosystems, Netherlands), which gives a quantitative result. For
biochemical measurements, the intra-assay coef®cients of variation
(CV) values ranged between 0.8± 2.1%, and the between-run CV
values ranged between 1.2±2.7%.
Statistical analysis
Statistical analysis was carried out with Wilcoxon Two Related-
Samples and Mann±Whitney tests. The data are expressed as means 6
SEM. Statistical signi®cance was set at P < 0.05 and the categorical
variables were expressed as percentages. Data were analysed using
SPSS (Statistical Package for the Social Science, version 10.0) for
Windows 98 (Microsoft Corp.).
Results
All of the women who were enrolled into the investigation
completed the study. The mean age of the subjects was 50.9 6
1.23 and 52.6 6 0.7 years, and their mean body mass index
(BMI) was 31.27 6 0.23 and 30.95 6 0.19 kg/m2 in the DM-
HRT and HT-HRT groups respectively. Two subjects (10%) in
the DM-HRT group and one subject (4.7%) in the HT-HRT
group complained about abnormal vaginal bleeding such as
metrorrhagia and four patients (19%) reported breast tender-
ness in the HT-HRT group. Other adverse effects were not
seen.
HRT was associated with statistically signi®cant decreases
in serum mean fasting glucose and fructosamine levels, and
with a non-signi®cant reduction in serum mean HbA1c level in
the DM-HRT group. Signi®cant changes were seen in mean
serum VLDL and HDL-cholesterol levels in the HT-HRT
group. The increase in mean serum Apo-A1 level and the
reduction in mean serum Apo-B level were statistically
signi®cant in both treatment groups. The changes in mean
serum lipid sub-fractions, fasting glucose, fructosamine and
HbA1c levels are given in Table I.
Serum CRP, creatinine, 24 h urine protein levels, creatinine
clearance and systolic and diastolic blood pressure did not change
signi®cantly during 12 weeks of transdermal HRT in both
groups. The baseline values and the effects of HRT on C-reactive
protein (CRP), creatinine, 24 h urine protein levels, creatinine
clearance and blood pressure are summarized in Table II.
Discussion
Diabetic patients have a high risk of cardiovascular disease and
dyslipidaemia (Niskanen et al., 1998; Kaukua et al., 2001;
Jacobsen et al., 2002). A number of studies have analysed the
effects of HRT on glucose and lipid metabolism or endothelial
function and markers in diabetic patients (Andersson et al.,
1997, 1999; Cornu et al., 2000; Aguilar-Salinas et al., 2001;
Darko et al., 2001; Ferrara et al., 2001; Friday et al., 2001;
Manning et al., 2001; Perera et al., 2001, 2002). Some previous
studies in type 2 diabetics suggested that HRT improved
glucose homeostasis (Brussaard et al., 1997a,b; Samaras et al.,
1999; Aguilar-Salinas et al., 2001; Ferrara et al., 2001; Friday
et al., 2001). Estrogen regulates insulin-induced glucose
transport through glucose transporters translocation in rat
skeletal muscle (Rincon et al., 1996). Contrary to these data it
was recently demonstrated that glucose utilization was lower in
postmenopausal women taking HRT in a human-study (Ryan
et al., 2002),
In this study, transdermal HRT did not have any worsening
effect on glucose metabolism in diabetic patients, moreover the
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mean serum fasting glucose and fructosamine levels decreased
signi®cantly. These outcomes were consistent with some
previous studies, which used the transdermal route for HRT
(Andersson et al., 1999; Duncan et al., 1999). On the other
hand the patients enrolled in this study had well-controlled
diabetic regulation. Glucose homeostasis and route of HRT
administration may contribute to the effect of estrogen on
glucose metabolism. In addition to these data, Cornu et al.
(2000) showed that there was no signi®cant difference between
the transdermal and oral routes for glucose homeostasis
criteria. In our hypertensive normo-glycaemic postmenopausal
women, transdermal HRT did not have any signi®cant effect on
glucose metabolism. These results were consistent with data
from the Postmenopausal Estrogens/progestins Intervention
(PEPI) trial (The Writing Group, 1995), which suggested that
the greatest bene®t concerning glucose metabolism was
achieved in patients who were hyperinsulinaemic at the
beginning of HRT.
The lipid pro®le in type 2 diabetic patients usually comprises
higher triglycerides and LDL-cholesterol, and lower HDL-
cholesterol (Lehto et al., 1997). Most of the studies that deal
with the effect of HRT on lipid metabolism have indicated that
there is an improvement in lipid pro®le (Hulley et al., 1998;
Samaras et al., 1999; Herrington et al., 2000; Manwaring et al.,
2000; Chen et al., 2001; Erenus et al., 2001; Shlipak et al., 2001;
Sendag et al., 2002). Effects of HRT on lipid metabolism due to
routes of administration are different. Although a reduction in
serum total cholesterol, LDL cholesterol or triglyceride levels
was seen in the transdermal route (Perrera et al., 2001; Ranta
et al., 2002; Sendag et al., 2002), it was suggested that the oral
route had a more favourable effect on lipid pro®le than the
transdermal route, except triglycerides (Darko et al., 2001;
Vehkavaara et al., 2001; Sendag et al., 2002).
The current study demonstrated that transdermal HRT
caused a signi®cant increase in Apo-A1 levels and a signi®cant
reduction in Apo-B levels and did not show any noteworthy
Table II. Effects of HRT on urine protein excretion and serum CRP, ®brinogen levels
Variable Diabetic + HRT (n=20) Hypertensive + HRT (n = 21)
Mean values P Mean values P
Urine protein mg/day Baseline 143.7 6 32.9 0.64 109 6 19.9 0.17
3 months 145.25 6 25.6 138.95 6 16.2
CRP mg/l Baseline 9.4 6 1.17 1 9.57 6 1.7 0.86
3 months 12.55 6 3.3 9.8 6 1.7
Serum creatinine mg/dl Baseline 0.83 6 0.016 0.25 0.85 6 0.018 0.82
3 months 0.85 6 0.016 0.86 6 0.017
Creatinine clearance ml/min Baseline 85.8 6 4.3 0.16 84.62 6 4.9 0.61
3 months 96.7 6 3.6 85.38 6 4.15
SBP mmHg Baseline 142.68 6 2.95 0.91 143.8 6 2.3 0.33
3 months 142.51 6 2.4 145 6 2.24
DBP mmHg Baseline 82.68 6 2.07 0.56 83.1 6 1.8 0.20
3 months 82.07 6 2.3 84.76 6 1.4
aP < 0.05 statistically signi®cant; P for the change between baseline and 3 months 6 SEM.
SBP = systolic blood pressure, DBP = diastolic blood pressure.
Table I. Effects of HRT on fasting glucose, fructosamine, glycated haemoglobin (HDA2C) fasting lipid fractions and apolipoproteins (Apo)
Fasting variables Diabetic + HRT (n = 20) Hypertensive + HRT (n = 21)
Mean values Change % P Mean values Change % P
Fasting glucose mg/dl Baseline 159.80 6 13.74 ±16.9 0.01 a 97.14 6 2.6 ±0.8 NS
3 months 132.85 6 9.2 96.38 6 2.7
HbA1c % Baseline 5.07 6 0.4 ±6.9 NS 3.73 6 0.13 ±2.4 NS
3 months 4.72 6 0.22 3.64 6 0.11
Fructosamine mol/ml Baseline 314.35 6 16.31 ±10.7 0.002 a 249.8 6 10.3 ±3.6 NS
3 months 252.50 6 6.3 240.66 6 7.1
Apo A1 mg/dl Baseline 10524 6 4.6 +21.9 0.001 a 112.57 6 3.1 +16.9 0.001 a
3 months 128.63 6 3.23 131.01 6 3.8
Apo B mg/dl Baseline 110.88 6 4.7 ±16.3 0.001 a 117.05 6 4.14 ±15.3 0.001 a
3 months 92.20 6 5.1 99.69 6 4.3
Total chol. mg/dl Baseline 225.55 6 8.73 ±9.5 NS (0.067) 219.47 6 8.7 ±2.6 NS
3 months 201.80 6 8.3 214 6 9.4
LDL-chol. mg/dl Baseline 122 6 6.53 ±4.9 NS 134.09 6 6.6 ±4.4 NS
3 months 116.05 6 7.15 128.66 6 9.4
VLDL-chol mg/dl Baseline 49.25 6 7.14 ±14.2 NS 38.14 6 3.0 ±28.9 0.006 a
3 months 41.75 6 4.84 27.61 6 5.2
HDL-chol. mg/dl Baseline 46.20 6 2.7 +7.9 NS (0.091) 47.95 6 2.9 +14.8 0.017 a
3 months 50.5 6 2.2 54.76 6 3.5
Triglyceride mg/dl Baseline 186.45 6 22.7 +9.4 NS 168.76 6 34.7 +5.9 NS
3 months 205.3 6 23.9 178.57 6 20.2
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harmful effect on lipid sub-fractions in all study subjects. For
instance, serum HDL-cholesterol levels increased by 14.8 and
7.9% in hypertensive normo-glycaemic (P < 0.05) and diabetic
patients (P = NS) respectively, and also there were no
signi®cant changes in total cholesterol, LDL cholesterol and
triglyceride levels in either treatment groups. These outcomes
might have been dependent on using short-term (3 months)
HRT and the transdermal route.
We kept antihypertensive medication constant during the
study period and HRT did not have any worsening effect on
mean blood pressure in high-risk postmenopausal women. It
was shown that HRT did not have an adverse effect on blood
pressure control in postmenopausal women (Szekacs et al.,
2000a). The neutral effects of estrogen on blood pressure might
have been achieved by the transdermal route (Af®nito et al.,
2001) or an improvement in parameters of macro-vascular
function such as endothelium-mediated vasodilatation by an
increase in the biological actions of nitric oxide and a decrease
in the action of angiotensin-converting enzyme (ACE) activity
(Bush et al., 1998; Gerhard et al., 1998; Konukoglu et al.,
2000; Cefalu, 2001; Nogawa et al., 2001).
This study showed that 3 months of transdermal HRT in
high-risk postmenopausal women did not have any adverse
effect on proteinuria and serum creatinine levels. Szekacs et al.
(2000b) demonstrated that HRT improved proteinuria in the
diabetic patient. The ability of estrogen to reduce oxidative
stress may be bene®cial to ameliorate nephropathy.
Elevated serum C-reactive protein was reported as a risk
factor for future cardiovascular events (Ridker et al., 1998).
CRP represents the increased proin¯ammatory effect and
increases plaque vulnerability and propensity to thrombosis
(Cushman et al., 1999a,b). Our subjects in this study comprised
high-risk postmenopausal women and there was not an increase
in CRP level. It was reported that HRT increased the risk of
new cardiovascular events occurring in the ®rst year and the
risk reduction occurred in subsequent years (Hulley et al.,
1998). Consistent with this is the observation that serum CRP
rapidly becomes elevated in healthy HRT users (Ridker et al.,
1999; van Baal et al., 1999), although, in our study groups,
using short-term transdermal HRT, we were unable to con®rm
this conclusion; an outcome consistent with the results of
Vehkavaara et al. (2001) and Prelevic et al. (2002).
There were many questions about the risk and bene®ts of
estrogen/progestin use in postmenopausal women. The outcomes
of the WHI study (Writing Group for the Women's Health
Initiative Investigators, 2002), which is a randomized placebo-
controlled trial, were derived from the use of a daily combined
regimen of conjugated equine estrogen (CEE) and medroxypro-
gesterone acetate (MPA) in postmenopausal women with an
intact uterus. Although no difference was seen in death rates
between the study groups, a small but signi®cantly increased risk
of non-fatal cardiac events was found in the postmenopausal
women using combined HRT, which in combination with an
increased risk of breast cancer led inevitably to a discontinuation
of the study. This outcome may not be valid for the transdermal
route of HRT administration, and also the fact that study subjects
were relatively older in this study than in the other studies might
have affected this result.
There were no detrimental effects of transdermal HRT on
lipid pro®le, glucose metabolism, CRP and urine protein levels
in our well-controlled, relatively younger diabetic or hyper-
tensive patients in short-term interval. Additional research will
be necessary to determine the effects of long-term transdermal
HRT in high-risk postmenopausal women.
We conclude that decisions about HRT should be taken on a
case-by-case basis, and in doing so it is important to include the
potential personal bene®ts and risk pro®le, especially in high-
risk postmenopausal women.
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